Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients

References

• Carnero Contentti E, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation. 2021 Sep 16;18(1):208.
   PubMed Web of Science ®Google Scholar
• Carnero Contentti E, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice[Mult Scler Relat Disord. 2020 Oct;45:102428]. Mult Scler Relat Disord. 2021 Jul;52:103026. Epub 2021 May 25. Erratum for: Mult Scler Relat Disord. 2020 Oct;45:102428.PMID: 34044260.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189.
   PubMed Web of Science ®Google Scholar
• Contentti EC, Lopez PA, Pettinicchi JP, et al. Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: data from a nationwide registry in Argentina. Mult Scler J Exp Transl Clin. 2021 Aug 20;7(3):20552173211032334.
   Google Scholar
• Palace J, Lin DY, Zeng D, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain. 2019;142:1310–1323.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Kessler RA, Rimler Z, et al. Mortality in neuromyelitis optica is strongly associated with African ancestry. Neurol Neuroimmunol Neuroinflamm. 2018;5:e468.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Ng J, Coleman J, et al. Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment. Mult Scler Relat Disord. 2019 Feb;28:60–63.
   PubMed Web of Science ®Google Scholar
• Seok JM, Cho EB, Lee HL, et al. Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder. J Neurol Sci. 2016 Sep 15; 368:209–213
   PubMed Web of Science ®Google Scholar
• Shi Z, Du Q, Chen H, et al. Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study. J Neurol. 2020 Apr;267(4):913–924.
   PubMed Web of Science ®Google Scholar
• Kessler RA, Mealy MA, Levy M. Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016 Jul 28; 3(5):e269.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Berthele A, Fujihara K, et al., Eculizumab in Aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–625.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Kleiter I, Fujihara K, et al., Trial of Satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114–2124.
   PubMed Web of Science ®Google Scholar
• Traboulsee A, Greenberg BM, Bennett JL, et al., Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402–412.
   PubMed Web of Science ®Google Scholar
• Cree BAC, Bennett JL, Kim HJ, et al., N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206): 1352–63. doi:https://doi.org/10.1016/S0140-6736(19)31817-3.
   Google Scholar
• Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79:206–216.
   PubMed Web of Science ®Google Scholar
• Jarius S, Paul F, Weinshenker BG, et al. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6:85.
   PubMed Web of Science ®Google Scholar
• Demuth S, Guillaume M, Bourre B, et al. Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. J Neuroinflammation. 2022 Mar 2;19(1):62.
   PubMed Web of Science ®Google Scholar
• Songthammawat T, Srisupa-Olan T, Siritho S, et al. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Mult Scler Relat Disord. 2020 Feb;38:101506.
   PubMed Web of Science ®Google Scholar
• Trebst C, Jarius S, Berthele A, et al., Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014 Jan;261(1):1–16.
   PubMed Web of Science ®Google Scholar
• Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler. 2016 Feb;22(2):185–192.
   PubMed Web of Science ®Google Scholar
• Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019 May 21; 6(4):e572.
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, O’Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999 Dec;46(6):878–886.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Nakazawa T, Doi H, et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol. 2010;248:1777–1785.
   PubMed Web of Science ®Google Scholar
• Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34:171–354.
   PubMed Web of Science ®Google Scholar
• Palace J, Leite MI, Jacob A. A practical guide to the treatment of neuromyelitis optica. Pract Neurol. 2012 Aug;12(4):209–214. Erratum in: Pract Neurol. 2012 Oct;12(5):342.Leite, Isobel [corrected to Leite, Maria Isabel].
   PubMedGoogle Scholar
• Kleiter I, Gahlen A, Borisow NF, et al. NEMOS (Neuromyelitis Optica Study Group). Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504.
   PubMed Web of Science ®Google Scholar
• Faer S, Nikolayczik J, Chan A, et al. Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Ther Adv Neurol Disord. 2016 Jul;9(4):281–286.
   PubMed Web of Science ®Google Scholar
• Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):346–351.
   PubMed Web of Science ®Google Scholar
• Restrepo-Aristizábal C, Giraldo LM, Giraldo YM, et al. PLEX: the best first-line treatment in nmosd attacks experience at a single center in Colombia. Heliyon. 2021 Apr 17; 7(4):e06811.
   PubMed Web of Science ®Google Scholar
• Siritho S, Nopsopon T, Pongpirul K. Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis. J Neurol. 2021 Dec;268(12):4549–4562.
   PubMed Web of Science ®Google Scholar
• Kosiyakul P, Songwisit S, Ungprasert P, et al. Effect of plasma exchange in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Ann Clin Transl Neurol. 2020 Nov;7(11):2094–2102.
   PubMed Web of Science ®Google Scholar
• Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. 2014;20(4):501–504.
   PubMed Web of Science ®Google Scholar
• Magraner MJ, Coret F, Casanova B. The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia. 2013 Mar;28(2):65–72. English, Spanish.
   PubMed Web of Science ®Google Scholar
• Absoud M, Brex P, Ciccarelli O, et al. A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). Health Technol Assess. 2017 May;21(31):1–50.
   PubMed Web of Science ®Google Scholar
• Li X, Tian DC, Fan M, et al. Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord. 2020;44:102325.
   PubMed Web of Science ®Google Scholar
• Levy M, Mealy MA. Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2014 Apr 24; 1(1):e5.
   PubMedGoogle Scholar
• Mealy MA, Levy M. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine (Baltimore). 2019;98(25):e15944.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Shin K, John G, et al. Bevacizumab is safe in acute relapses of neuromyelitis optica. Clin Exp Neuroimmunol. 2015;6(4):413–418.
   PubMedGoogle Scholar
• Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology. 2011;76(1):87–93.
   PubMed Web of Science ®Google Scholar
• Collins J, Jones L, Snyder M, et al. A novel anti‐FcRn monoclonal antibody, is well tolerated in healthy subjects and reduces plasma IgG following subcutaneous or intravenous administration. In: 2019 American Academy of Neurology Annual Meeting. Philadelphia, PA; 2019.
   Google Scholar
• Young RE, Thompson RD, Larbi KY, et al. Neutrophil elastase (NE)-deficient mice demonstrate a nonredundant role for NE in neutrophil migration, generation of proinflammatory mediators, and phagocytosis in response to zymosan particles in vivo. J Immunol. 2004;172:4493–4502.
   PubMed Web of Science ®Google Scholar
• Papayannopoulos V, Metzler KD, Hakkim A, et al. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol. 2010;191:677–691.
   PubMed Web of Science ®Google Scholar
• Iwata K, Doi A, Ohji G, et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. Intern Med. 2010;49:2423–2432.
   PubMed Web of Science ®Google Scholar
• Araki M, Yamamura T. Neuromyelitis optica spectrum disorders: emerging therapies. Clin Exp Neuroimmunol. 2017;8(2):107–116.
   Google Scholar
• Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98.
   PubMed Web of Science ®Google Scholar